|
KMID : 0371420190970050223
|
|
Annals of Surgical Treatment and Research
2019 Volume.97 No. 5 p.223 ~ p.229
|
|
|
Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor
|
|
Park Je-Hyung
Kim Hyun-Yul
Jung Youn-Joo
Kim Dong-Il
Kim Jee-Yeon
Paik Hyun-June
|
|
|
Abstract
|
|
|
Purpose: Core needle biopsy (CNB) is a widely used procedure for breast cancer diagnosis and analyzing results of immunohistochemistry (IHC). Several studies have shown concordance or discordance in IHC results between CNB and surgical specimens (SS). A double-check (CNB and SS) is inefficient and costly to perform a double-check on all patients. Therefore, it is important to determine which patients would benefit from a double-check.
Methods: We collected the medical records of patients who underwent breast cancer surgery at Pusan National University Yangsan Hospital between April 2009 and June 2018 (n = 620). Molecular subtypes were classified as follows by hormone receptors (HR) and human epidermal growth factor receptor-2 (HER2): HR+/HER2+, HR+/HER2?, HR?/HER2+, HR?/HER2?. Clinicopathological factors including age, obesity, histological grade, preoperative CEA, CA15-3, T stage, N stage, and menopausal status were assessed to determine whether they were associated with subtype change.
Results: Increasing histological grade (P < 0.001; odds ratio [OR], 3.693; 95% confidence interval [CI], 1.941?7.025), preoperative CEA ≥ 5 ng/mL (P =0.042; OR, 2.399; 95% CI, 1.009?5.707) and higher T stage (P = 0.015; OR, 2.241; 95% CI, 1.152?4.357) were significantly associated with subtype change. On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031?1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088?6.490).
Conclusion: Patients with moderate- to high-grade tumors or CEA ≥ 5 ng/mL are required a double-check to determine the molecular subtype of breast cancer.
|
|
|
KEYWORD
|
|
|
Adjuvant, Biopsy, Breast neoplasms, Chemotherapy, Immunohistochemistry, Large-core needle
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|